Optimi Health Corp. (OPTI) — Optimi Health, a Health Canada-licensed GMP manufacturer, completed its first 2026 production cycle of 1,000 MDMA capsules (60 mg) and 1,000 naturally derived psilocybin capsules (5 mg) destined for Australia under that country's Authorised Prescriber Scheme.
The batch reinforces Optimi's role as a commercial supplier feeding Australia's regulated psychedelic-assisted therapy market, including insurer-backed programs. The run demonstrates ongoing revenue-generating drug supply while many peers remain pre-commercial.
Source: biospace.com
For the rest of that week's sector news, read our week in review.